Selective Inhibition of Glucagon and Insulin Secretion by Somatostatin Analogs 1

Abstract

Summary

The effects of somatostatin and 10 structural analogs of SRIF on arginine stimulated glucagon and insulin secretion were studied in isolated rat pancreas perfusions. All analog data were compared with the inhibitory effects of SRIF. It was observed that structural modifications could produce clear cut dissociation of the inhibitory effects on glucagon vs. insulin secretion. Four compounds which seem to have little effect on insulin release, but compared with SRIF have an enhanced inhibitory effect on glucagon release, are of potential interest in the therapy of diabetes. These compounds are DCys¹⁴; DTrp⁸, DCys¹⁴; Ala², DTrp⁸, DCys¹⁴; and CGln (Gly)₂, DTrp⁸ somatostatin.